Drug prices in the United States are nearly three times higher than in other developed countries. For every dollar paid for prescription drugs in 33 comparable nations, U.S. consumers pay $2.78. The reasons behind this gap aren’t simple, and no single villain explains the trend. A tangled system of middlemen, patent strategies, development costs, and weak price regulation all push prices upward.
The Middleman Problem
Between a drug manufacturer and the patient who swallows the pill sits a chain of intermediaries, each taking a cut. Wholesalers, pharmacies, and pharmacy benefit managers (PBMs) all add margins. According to a 2024 analysis from the U.S. Department of Health and Human Services, wholesalers take roughly 5 to 6 percent on average across all drugs, while pharmacies take about 3 percent. Those numbers look modest until you examine generic drugs separately: wholesalers mark up generics by about 40 percent, pharmacies by 36 percent, and PBMs by a striking 54 percent.
PBMs deserve special attention because they create a perverse incentive loop. These companies negotiate rebates and discounts from drug manufacturers in exchange for placing drugs on preferred formulary lists. But those rebates rarely reach consumers. Instead, they flow to the PBMs as profit. Manufacturers respond by raising their list prices to offset the rebates they’re paying out. PBMs actually benefit from this cycle because their rebate revenue grows as list prices climb. A review in Missouri Medicine put it bluntly: drug manufacturers raise their prices because of PBMs, and PBMs encourage this practice because they profit more from expensive drugs.
Patent Strategies That Block Competition
Generic drugs are the main mechanism for bringing prices down. When a patent expires, competitors can produce the same medication for a fraction of the cost. Pharmaceutical companies know this, and many use aggressive legal strategies to delay that moment as long as possible.
The most common tactic is called “evergreening.” Rather than relying on the original patent, a company files new patents on minor variations of the drug: a different salt form, a new crystal structure, a slightly modified delivery mechanism. Each new patent has a later expiration date, effectively extending the company’s monopoly well beyond the original term. A European Commission investigation found that blockbuster medicines can be protected by up to 100 patent bundles, and in one extreme case, a single drug was surrounded by 1,300 patents and applications across EU member states.
This creates what regulators call a “patent thicket,” a minefield of overlapping intellectual property that generic manufacturers must navigate. Even if a generic company suspects most of these patents wouldn’t hold up in court, the legal risk and cost of challenging them is enormous. The strategy works not because every patent is strong, but because the sheer volume creates enough uncertainty to discourage or delay generic competitors from entering the market at all.
What It Actually Costs to Develop a Drug
Manufacturers frequently point to research and development costs as the primary driver of high prices, and the numbers are genuinely large. A 2024 study in JAMA Network Open estimated the average cost of developing a new drug at about $173 million for successful compounds alone. Once you factor in the cost of all the failed candidates that never made it to market, that figure jumps to $516 million. Add in the cost of capital (the money tied up for years during development that could have been invested elsewhere), and the total reaches roughly $879 million per drug.
These costs are real, but they don’t fully explain pricing decisions. Many of the most expensive drugs on the market had their initial research funded partly by government grants or academic institutions. And once a drug recoups its development costs, prices rarely come down. The R&D argument explains why new drugs launch at high prices. It doesn’t explain why prices on existing drugs continue climbing year after year.
Orphan Drugs and Small Patient Populations
The Orphan Drug Act of 1983 was designed to encourage companies to develop treatments for rare diseases, those affecting fewer than 200,000 patients in the U.S. It offers tax credits, streamlined approval, and seven years of exclusive marketing rights. The law succeeded at spurring development, but it also created a pricing dynamic with few natural limits.
Orphan drugs can cost hundreds of thousands of dollars per patient per year. Insurers have historically covered them without much pushback because the small patient populations meant the total cost exposure seemed manageable. But the number of orphan drug approvals has grown dramatically, and some drugs initially approved for rare conditions later expand to treat broader populations while retaining their premium pricing. The combination of guaranteed exclusivity and minimal price resistance has made orphan drugs one of the fastest-growing categories of pharmaceutical spending.
How Patients Feel the Impact
Even when list prices rise, manufacturers and insurers often point to rebates and discounts that lower the “net” price. But patients frequently pay based on the list price, not the net price, especially those with high-deductible insurance plans or coinsurance structures tied to a drug’s sticker cost.
The data reflects this. The share of patients facing any out-of-pocket costs for brand-name drugs administered by clinicians rose from 38 percent in 2009 to 48 percent in 2018. Among those paying something, median annual out-of-pocket costs more than doubled during that period, climbing from $351 to $768 after adjusting for inflation. That works out to roughly 9.6 percent growth per year, far outpacing general inflation.
The U.S. Lacks the Price Controls Other Countries Use
Most other wealthy nations negotiate drug prices at a national level or set maximum prices based on a drug’s demonstrated value. The U.S. has historically done neither for the majority of the market. Medicare, the largest single purchaser of prescription drugs in the country, was explicitly prohibited from negotiating prices until recently.
The Inflation Reduction Act of 2022 changed this for a small subset of drugs. Medicare selected its first 10 medications for price negotiation, including widely used treatments like Eliquis (a blood thinner), Jardiance (for diabetes and heart failure), and Entresto (for heart failure). Negotiated prices for these drugs will take effect in 2026. This is a meaningful first step, but it covers only a handful of the thousands of drugs Medicare pays for, and it doesn’t touch the commercial insurance market at all.
Overall Spending Is Still Climbing
Here’s a nuance that often gets lost: in the most recent data, average drug prices themselves were essentially flat. Total U.S. pharmaceutical spending grew 10.2 percent in 2024, reaching $805.9 billion. But that growth was driven almost entirely by increased utilization (more prescriptions being filled, up 7.9 percent) and the launch of expensive new drugs (contributing 2.5 percent), while average prices across existing drugs actually dipped by 0.2 percent.
This distinction matters. The sticker price on any individual drug may not be rising much in a given year, but the overall cost burden keeps growing because more people are taking more medications, and the newest drugs entering the market launch at higher price points than ever. A system that controls the price of existing drugs but places no limits on launch prices for new ones will continue to see total costs escalate. For patients picking up prescriptions at the pharmacy, the practical difference between “your drug costs more” and “you now need a drug that costs more” is essentially zero.